User:Cutter J. Koehler/Sandbox1
From Proteopedia
| (4 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
== Human metabotropic glutamate receptor 5 transmembrane domain == | == Human metabotropic glutamate receptor 5 transmembrane domain == | ||
<StructureSection load='4oo9' size='350' frame='true' side='right' caption='Human metabotropic glutamate receptor 5 transmembrane domain' <'scene='(Ionic_lock)'> | <StructureSection load='4oo9' size='350' frame='true' side='right' caption='Human metabotropic glutamate receptor 5 transmembrane domain' <'scene='(Ionic_lock)'> | ||
| - | + | The Human metabotropic glutamate receptor 5 transmembrane domain is a | |
| - | + | ||
== Structure== | == Structure== | ||
| Line 9: | Line 8: | ||
=== Ionic Locks === | === Ionic Locks === | ||
This is the <scene name='72/726428/Ionic_lock/2'>Ionic Lock in inactive state</scene>. | This is the <scene name='72/726428/Ionic_lock/2'>Ionic Lock in inactive state</scene>. | ||
| + | <font color='dark green'><b>test here</b></font> | ||
| - | == Function == | + | == Function and Pathway == |
| + | [http://www.researchgate.net/publication/263354624_Mavoglurant_as_a_treatment_for_Parkinson's_disease Mavoglurant as a treatment for Parkinson's disease] | ||
| + | |||
| + | [http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293 Pharmacology of mGlu5 receptors ] | ||
| + | |||
| + | [http://en.wikipedia.org/wiki/Glutamate_receptor Glutamate signaling pathway and receptors general overview] | ||
== Disease == | == Disease == | ||
| Line 24: | Line 29: | ||
== References == | == References == | ||
<references/> | <references/> | ||
| + | 1.Clemmensen, C., Smajilovic, S., Wellendorph, P., and Brauner-Osborne, H. (2013). “The GPCR, class C, group 6, subtype A (GPCR6A) receptor: from cloning to physiological function.” British Journal of Pharmacology. 171: 1129-41. | ||
| + | |||
| + | 2. Dore, Andrew S., Okrasa, Krzysztof, Okrasa., Patel,, Jayesh, C., Serrano-Vega, Maria., Bennett, Kirstie., Cooke, Robert M., Errey, James C., Jazayeri, Ali., Khan, Samir., Tehan, Ben., Weir, Malcolm., Wiggin, Giselle R., Marshall, Fiona H. (2014) “Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain.” Nature. 511: 557-62. | ||
| + | |||
| + | 3.Feng, Zhiwei, Shifan Ma, Guanxing Hu, and Xiang-Qun Xie.(2015). "Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family." The AAPS Journal AAPS J 17.3 (2015): 737-53. | ||
| + | 4Niswender, Colleen M., and P. Jeffrey Conn.(2010). "Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease." Annu. Rev. Pharmacol. Toxicol. Annual Review of Pharmacology and Toxicology 50.1: 295-322. Web. | ||
| + | |||
| + | 5"Novartis Announces Results of Mavoglurant (mGluR5) (AFQ056) Clinical Trials and the Conclusion of the Long-Term Extension Study" (2014). NFXF. Foward, 24 Apr. Web. | ||
| + | |||
| + | 6. Wu, Huixian, Wang, Chong, Gregory, Karen J., Han, Gye W., Cho, Hyekyung P., Xia, Yan, Niswender, Colleen M., Katritch, Vsevolod, Meiler, Jens, Cherezov, Vadim, Conn, P.J., Stevens, Raymond C. (2014) “Structure of class C GPCR metabotropic glutamate receptor 1 Bound to an Allosteric Modulator.” Science. 344: 58-64. | ||
| + | |||
| + | 7. Woodcook, Elizabeth A., Kistler, Peter M., Ju, Yue-Kun. (2009) “Phosphoinositide signalling and cardiac arrhythmias.” European Society of Cardiology. 82: 286-95. | ||
| + | 8."4009."(2014). Structure of the Human Class C GPCR Metabotropic Glutamate Receptor 5 Transmembrane Domain in Complex with the Negative Allosteric Modulator Mavoglurant. RCSB PDB, n.d. Web. 22 Feb. 2016 | ||
Current revision
Human metabotropic glutamate receptor 5 transmembrane domain
| |||||||||||
References
1.Clemmensen, C., Smajilovic, S., Wellendorph, P., and Brauner-Osborne, H. (2013). “The GPCR, class C, group 6, subtype A (GPCR6A) receptor: from cloning to physiological function.” British Journal of Pharmacology. 171: 1129-41.
2. Dore, Andrew S., Okrasa, Krzysztof, Okrasa., Patel,, Jayesh, C., Serrano-Vega, Maria., Bennett, Kirstie., Cooke, Robert M., Errey, James C., Jazayeri, Ali., Khan, Samir., Tehan, Ben., Weir, Malcolm., Wiggin, Giselle R., Marshall, Fiona H. (2014) “Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain.” Nature. 511: 557-62.
3.Feng, Zhiwei, Shifan Ma, Guanxing Hu, and Xiang-Qun Xie.(2015). "Allosteric Binding Site and Activation Mechanism of Class C G-Protein Coupled Receptors: Metabotropic Glutamate Receptor Family." The AAPS Journal AAPS J 17.3 (2015): 737-53. 4Niswender, Colleen M., and P. Jeffrey Conn.(2010). "Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease." Annu. Rev. Pharmacol. Toxicol. Annual Review of Pharmacology and Toxicology 50.1: 295-322. Web.
5"Novartis Announces Results of Mavoglurant (mGluR5) (AFQ056) Clinical Trials and the Conclusion of the Long-Term Extension Study" (2014). NFXF. Foward, 24 Apr. Web.
6. Wu, Huixian, Wang, Chong, Gregory, Karen J., Han, Gye W., Cho, Hyekyung P., Xia, Yan, Niswender, Colleen M., Katritch, Vsevolod, Meiler, Jens, Cherezov, Vadim, Conn, P.J., Stevens, Raymond C. (2014) “Structure of class C GPCR metabotropic glutamate receptor 1 Bound to an Allosteric Modulator.” Science. 344: 58-64.
7. Woodcook, Elizabeth A., Kistler, Peter M., Ju, Yue-Kun. (2009) “Phosphoinositide signalling and cardiac arrhythmias.” European Society of Cardiology. 82: 286-95. 8."4009."(2014). Structure of the Human Class C GPCR Metabotropic Glutamate Receptor 5 Transmembrane Domain in Complex with the Negative Allosteric Modulator Mavoglurant. RCSB PDB, n.d. Web. 22 Feb. 2016
